|
Video: What is a Stock Split?
|
|
Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. Co. has marketed Korlym (mifepristone) in the U.S. for the treatment of patients with Cushing's syndrome. Co.'s primary compounds have entered the clinic as potential treatments for serious disorders, including Cushing's syndrome, solid tumors (such as ovarian cancer, castration-resistant prostate cancer and adrenocortical cancer with cortisol excess), antipsychotic induced weight gain and non-alcoholic steatohepatitis. According to our Corcept Therapeutics stock split history records, Corcept Therapeutics has had 0 splits. | |
|
Corcept Therapeutics (CORT) has 0 splits in our Corcept Therapeutics stock split history database.
Looking at the Corcept Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Corcept Therapeutics shares, starting with a $10,000 purchase of CORT, presented on a split-history-adjusted basis factoring in the complete Corcept Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/06/2014 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$4.02 |
|
End price/share: |
$24.52 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
509.95% |
|
Average Annual Total Return: |
19.82% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$60,994.85 |
|
Years: |
10.00 |
|
|
|
|
|